Avtozma™

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Rheumatoid Arthritis (IV and SC formulations) Avtozma is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients in combination with methotrexate (MTX) or other non-biological disease- modifying anti-rheumatic drugs (DMARDs) in case of either an inadequate response or intolerance to previous therapy with one or more DMARDs. Avtozma is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients with poor prognostic factors (see section 5.1 Pharmacodynamic Properties, Clinical Trials) in combination with MTX in those not previously treated with MTX. In the two groups of patients above, Avtozma can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. Avtozma has been shown to inhibit the progression of joint damage in adults, as measured by X-ray, when given in combination with methotrexate. Giant Cell Arteritis (SC formulations only) Avtozma is indicated for the treatment of giant cell arteritis (GCA) in adult patients. Polyarticular Juvenile Idiopathic Arthritis (IV and SC formulations) Avtozma is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to or intolerance to methotrexate (MTX). Avtozma can be given alone or in combination with MTX. Systemic Juvenile Idiopathic Arthritis (IV and SC formulations) Intravenous formulation Avtozma is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. Subcutaneous formulation Avtozma is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 1 year of age and older. Avtozma IV and SC can be given alone or in combination with methotrexate (MTX). Cytokine Release Syndrome (CRS) (IV formulation only) Avtozma is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.

Source: ARTG

• Shelf lifetime is 36 Months
• Store at 2 to 8 degrees Celsius
• Protect from Light; Do not Freeze; Refrigerate; See Product information for shelf life

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, solution
• Subcutaneous
• Clear to slightly opalescent, colourless to yellowish sterile solution

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1
• 12
• 4

Source: ARTG

This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.

Source: PBS

For the active ingredient: Tocilizumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).